Assignee
MYOKARDIA INC
US·12 granted patents·30 pending applications·67 citations·filing 2014–2025
Top patents by PatentIndex Score
42 records- 0194US9181200B2Pyrimidinedione compoundsMYOKARDIA INC·Filed 2014·Granted Nov 10, 2015·22 cites·19 claims
- 0293US9663516B2Bicyclic-pyrimidinedione compoundsMYOKARDIA INC·Filed 2015·Granted May 30, 2017·10 cites·31 claims
- 0393US9199945B2Cycloalkyl-substituted pyrimidinedione compoundsMYOKARDIA INC·Filed 2014·Granted Dec 1, 2015·12 cites·20 claims
- 0492US9925177B24-methylsulfonyl-substituted piperidine urea compoundsMYOKARDIA INC·Filed 2016·Granted Mar 27, 2018·16 cites·35 claims
- 0588US2024382486A1Pyrimidinedione compoundsMYOKARDIA INC·Filed 2024·Application pending·0 cites
- 0687US9585883B2Pyrimidinedione compoundsMYOKARDIA INC·Filed 2015·Granted Mar 7, 2017·5 cites·18 claims
- 0785US11123337B24-methylsulfonyl-substituted piperidine urea compoundsMYOKARDIA INC·Filed 2020·Granted Sep 21, 2021·1 cites·14 claims
- 0885US2025275952A14-methylsulfonyl-substituted piperidine urea compoundsMYOKARDIA INC·Filed 2024·Application pending·0 cites
- 0985US2026007671A1Treatment of hcm with pyrimidinedione compoundsMYOKARDIA INC·Filed 2025·Application pending·0 cites
- 1084US2025282779A1Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseasesMYOKARDIA INC·Filed 2025·Application pending·0 cites
- 1184US2024423981A1Treatment of hcm with pyrimidinedione compoundsMYOKARDIA INC·Filed 2024·Application pending·0 cites
- 1283US10758525B24-methylsulfonyl-substituted piperidine urea compoundsMYOKARDIA INC·Filed 2018·Granted Sep 1, 2020·1 cites·36 claims
- 1383US2023165860A1Pyrimidinedione compoundsMYOKARDIA INC·Filed 2023·Application pending·0 cites
- 1482US12344607B2Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseasesMYOKARDIA INC·Filed 2023·Granted Jul 1, 2025·0 cites·15 claims
- 1582US2025360132A1Methods of administering myosin inhibitorsMYOKARDIA INC·Filed 2025·Application pending·0 cites
- 1680USRE50050EPyrimidinedione compoundsMYOKARDIA INC·Filed 2022·Granted Jul 23, 2024·0 cites·23 claims
- 1779US2024115568A1Methods of Administering Myosin InhibitorsMYOKARDIA INC·Filed 2023·Application pending·0 cites
- 1878US2023338378A1Methods of Administering Myosin InhibitorsMYOKARDIA INC·Filed 2023·Application pending·0 cites
- 1978US2025288586A1Methods of Administering Myosin InhibitorsMYOKARDIA INC·Filed 2023·Application pending·0 cites
- 2077US11034693B2Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseasesMYOKARDIA INC·Filed 2019·Granted Jun 15, 2021·0 cites·42 claims
- 2177US2025213565A1Treatment of hcm with pyrimidinedione compoundsMYOKARDIA INC·Filed 2025·Application pending·0 cites
- 2277US2022313695A1Treatment of hcm with pyrimidinedione compoundsMYOKARDIA INC·Filed 2022·Application pending·0 cites
- 2377US2022340569A1Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseasesMYOKARDIA INC·Filed 2022·Application pending·0 cites
- 2476US2022226324A1Treatment of hcm with pyrimidinedione compoundsMYOKARDIA INC·Filed 2022·Application pending·0 cites
- 2576US2022106314A1Substituted 5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4-diones for treating cardiac diseasesMYOKARDIA INC·Filed 2021·Application pending·0 cites
- 2675US2025241903A1Treatment of systolic dysfunctionMYOKARDIA INC·Filed 2024·Application pending·0 cites
- 2774US2021346379A1Pyrimidinedione compoundsMYOKARDIA INC·Filed 2021·Application pending·0 cites
- 2873US2022117955A14-methylsulfonyl-substituted piperidine urea compoundsMYOKARDIA INC·Filed 2021·Application pending·0 cites
- 2972US2020297726A1Pyrimidinedione compoundsMYOKARDIA INC·Filed 2020·Application pending·0 cites
- 3071US2020054636A1Treatment of hcm with pyrimidinedione compoundsMYOKARDIA INC·Filed 2019·Application pending·0 cites
- 3165US2025325531A1Treatment of systolic dysfunctionMYOKARDIA INC·Filed 2024·Application pending·0 cites
- 3265US2018311242A1Pyrimidinedione compoundsMYOKARDIA INC·Filed 2018·Application pending·0 cites
- 3362US2017281626A1Pyrimidinedione compoundsMYOKARDIA INC·Filed 2017·Application pending·0 cites
- 3457US12459919B2Polymorphic forms of (R)-4-(1-((3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)sulfonyl)-1- fluoroethyl)-N-(isoxazol-3-yl)piperidine-1-carboxamideMYOKARDIA INC·Filed 2022·Granted Nov 4, 2025·0 cites·38 claims
- 3557US2022265629A1Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamideMYOKARDIA INC·Filed 2020·Application pending·0 cites
- 3654US2024299390A1Methods of Treatment with Myosin ModulatorMYOKARDIA INC·Filed 2021·Application pending·0 cites
- 3751US2016031862A1Cycloalkyl-substituted pyrimidinedione compoundsMYOKARDIA INC·Filed 2015·Application pending·0 cites
- 3851US2025034129A1CRYSTALLINE FORMS OF (6S,7S)-6-FLUORO-7-(2-FLUORO-5-METHYLPHENYL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)-5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINE-2,4(1H,3H)-DIONEMYOKARDIA INC·Filed 2023·Application pending·0 cites
- 3950US2023233545A1Treatment of atrial dysfunctionMYOKARDIA INC·Filed 2021·Application pending·0 cites
- 4048US2021053939A1Polymorphic forms of (r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamideMYOKARDIA INC·Filed 2020·Application pending·0 cites
- 4143US11873289B2Pyrazole compounds and preparation thereofMYOKARDIA INC·Filed 2019·Granted Jan 16, 2024·0 cites·32 claims
- 4240US2023158027A1Methods of treatment with myosin modulatorMYOKARDIA INC·Filed 2020·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →